检索结果-南通市图书馆

First-line cisplatin,docetaxel,and cetuximab for patients with recurrent or metastatic head and neck cancer:A multicenter cohort study

引用

World Journal of Clinical Oncology 2022年第2期13卷 147-158页

作者： Agustin Falco Mariano Leiva Albano Blanco Guido Cefarelli Andres Rodriguez Juan Melo Federico Cayol Manglio Miguel Rizzo Alejandro Sola Hernan Rodriguez Montani Matias Chacon Diego Enrico Federico Waisberg Department of Medical Oncology Head and Neck UnitAlexander Fleming Cancer InstituteBuenos Aires 1428Argentina Department of Medical Oncology Alexander Fleming Cancer InstituteBuenos Aires 1426Argentina Department of Medical Oncology Hospital Italiano de Buenos AiresBuenos Aires 1199Argentina Department of Medical Oncology Hospital Universitario AustralPilar 1629Argentina Department of Medical Oncology Fundación Centro Oncológico de Integración RegionalMendoza 5500Argentina Department of Medical Oncology Hospital Italiano RosarioSanatorio de la MujerRosario 2001Argentina

BACKGROUND The targeted therapy cetuximab[directed at the epidermal growth factor receptor(EGFR)]in combination with 5-fluorouracil and platinum-based chemotherapy(the EXTREME regimen)has shown substantial efficacy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck(R/M SCCHN).Thus,this scheme has been established as the preferred first-line option for these ***,more recently,a new strategy combining platinum,taxanes,and cetuximab(the TPEx regimen)has demonstrated similar efficacy with a more favorable toxicity profile in clinical *** To evaluate the safety and efficacy of the TPEx scheme as first-line therapy in advanced SCCHN in a multicenter cohort *** This retrospective multicenter cohort study included patients with histologically confirmed recurrent or metastatic SCCHN treated with first-line TPEx at five medical centers in Argentina between January 1,2017 and April 31,*** consisted of four cycles of docetaxel,cisplatin,and cetuximab followed by cetuximab maintenance *** outcomes and toxicity profiles were collected from medical *** response was assessed by the investigator in accordance with Response Evaluation Criteria in Solid Tumors(version 1.1).Adverse events were graded according to the National cancer Institute Common Terminology Criteria for Adverse Events(version 4.0).RESULTS Twenty-four patients were *** median age at diagnosis was 58 years(range:36-77 years).The majority of patients(83.3%)received at least four chemotherapy cycles in the initial *** the included group,the overall response rate was 62.5%,and 3 patients achieved a complete response(12.5%).The median time to response was 2.4 mo[95% confidence interval(CI):1.3-3.5].With a median follow-up of 12.7 mo(95%CI:8.8-16.6),the median progression-free survival(PFS)was 6.9 mo(95%CI:6.5-7.3),and the overall survival rate at 12 mo was 82.4%.Patients with documented tumor response s

关键词： recurrent and/or metastatic head and neck cancer TPEx schema Cetuximab Docetaxel Cisplatin First-line

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：